First-in-Man, First In The USA: What’s The Difference?

Slides:



Advertisements
Similar presentations
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Advertisements

Strengthening the Medical Device Clinical Trial Enterprise
510k Submission Overview Myraqa, Inc. August 22, 2012.
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Stages of drug development
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Understanding the Pre-IDE Program: FDA Perspective
Medicare Submission for Pre-Approval in Clinical Research Ronda Sharp, R.N., B.S.N., C.C.R.C. Clinical Research Facilitator Methodist Research Institute.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Investigational Devices and Humanitarian Use Devices June 2007.
AMERICAS | ASIA PACIFIC | EMEA Medical Devices: Concept to Commercialization How to avoid delays in getting your product cleared/approved by FDA Robert.
E-Clinical
FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.
Drug Development Process Stages involved in Regulating Drugs
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
Strengthening the Medical Device Clinical Trial Enterprise
Clinical trials for medical devices: FDA and the IDE process
Rachel Neubrander, PhD Division of Cardiovascular Devices
The CRT of EFS Where We’ve Been and Where We’re Going
What should be the optimal Design for TAVI Procedure.
Research Master ID (RMID)
Clinical Trial Design for Second Generation TAVI - Academic View
What Are the FDA Requirements for Submitting an IDE?
Andrew Farb, MD Division of Cardiovascular Devices
Hina M. Pinto, MSE Scientific Reviewer
Regulatory Basics: Europe and the CE Mark
Sponsor perspective of clinical research with clinical accounts
U.S. FDA Center for Devices and Radiological Health Update
OUS Data: What does the CE Mark Really Mean?
VenaSeal Closure System Utilization of the Pre-Submission Process & Interactive Review Sponsor’s Perspective 24 February 2015.
Adherence to the Labeling
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
Premarket Notification 510(k) process
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
The Information Professional’s Role in Product Safety
FDA’s IDE Decisions and Communications
How to Put Together an IDE Application
Clinical Trials — A Closer Look
Balancing Pre and Postmarket Requirements Different Scenarios
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
The State of Early Feasibility Studies in the US
Bioabsorbable DES and Biodegradable Polymers – FDA View
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
The FDA Early Feasibility Study Pilot and the Innovation Pathway
Japan-USA Synergies: Academic View
FIM in USA: Impact on the Landscape of Innovation
The Current PMA Requirements
FDA Guidance on Early Feasibility Studies, Including First-in-Human
Clinical Trials Medical Interventions
Laura Mauri, MD, MSc Brigham and Women’s Hospital
What Kind of Aspects can Physicians Look Forward To? US Physician View
Opportunities to Study Valve Iterations and Modifications in the US
Deputy Director, Division of Biostatistics No Conflict of Interest
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Regulatory Challenges for Biodegradable Scaffold Approval
Benefits of US EFS: A Clinical Perspective
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Early Feasibility in the USA –An Academic View
US Early Feasibility Studies (EFS)
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Erica Takai, PhD for Andrew Farb, M.D.
Research Master ID (RMID)
Clinical Trials.
Implantable Medical Devices: Accelerating Standards Development to Streamline Regulation Joshua Price | August 2,
How and why this study may change my practice ?
FDA Perspective Marco Cannella, PhD Senior Lead Reviewer
Opening an IND: Investigator Perspective
Pharmaceuticals Industry
Presentation transcript:

First-in-Man, First In The USA: What’s The Difference? Ron Waksman, MD, FACC, FSCAI Professor of Medicine, Georgetown University, Associate Chief of Cardiology, Washington Hospital Center, Washington DC

Ron Waksman, MD Consulting Fee Abbott Laboratories Biotronik, Inc. Boston Scientific Corporation Medtronic, Inc. Merck and Company, Inc.

Honoraria Abbott Laboratories Boston Scientific Corporation Medtronic, Inc. Consulting Fee Merck and Company, Inc.

What is First-In-Man Study? FIM is the culmination of the pre-clinical device development “ecosystem” A FIM trial tests the new device in humans for the first time Generally, these trials are small in size and in very select patient populations (eg: stable patients with de novo lesions, etc.) Bench Testing Animal Safety Testing Pre-clinical Animal Studies First-in-Man Clinical Trial

Status of FIM Trials in the US Although device innovation continues to emerge from the US the initiation of the device development has moved to non-US sites Why? FDA’s requirements can be an impediment to early clinical testing of new devices FIM trials need the same rigorous IDE application as a pivotal trial (average time to IDE approval is 14 months) The cost associated with obtaining an IDE are very high Implications! These new devices will either not become available to the US public or emerge into the US market much later than the rest of the global market FDA Impact on U.S. Medical Technology Innovation: A Survey of Over 200 Medical Technology Companies • November 2010 http://www.advamed.org/NR/rdonlyres/040E6C33-380B-4F6B-AB58-9AB1C0A7A3CF/0/makowerreportfinal.pdf 5

Status of FIM Trials in the US Average Time By Stage For PMA Product Average per month Expenditure By Stage For PMA Product FDA Impact on U.S. Medical Technology Innovation: A Survey of Over 200 Medical Technology Companies • November 2010 http://www.advamed.org/NR/rdonlyres/040E6C33-380B-4F6B-AB58-9AB1C0A7A3CF/0/makowerreportfinal.pdf 6

First-in-the-US Investigation What is it? A proposed track for devices already tested outside the US (with or without OUS approval) that established relatively safe profiles Investigations would be limited to up to 100 patients at no more than 5 experienced US centers 7

First-in-the-US Investigation Intended Users? This proposed track would be available only to sponsors that intend to complete an IDE submission for a pivotal trial or pursue an PMA 8

First-in-the-US Investigation Brief Requirements: Required to have prior human experience (minimum 100 patients) with at least 6 months follow up Minimum requirements to initiate this Investigation will be less than a traditional IDE Completion of current IDE requirements may be submitted throughout First-in-the-US Investigation 9

First-in-the-US Investigation Implication on Patients: US patients will have an opportunity to be a part of early novel device evaluation Patients will be fully informed of the potential additional risk involved in being a part of such early device investigations 10

First-in-the-US Investigation Implication on Sponsors: Motivate sponsors to return to the US for early clinical investigations Streamline the US human subject investigation into the pivotal trial Allow for streamlining US track milestones to be reached (eg first patient in US, entering US market) Allows for data combination from both this track and pivotal trials for the PMA application 11

First-in-the-US Investigation Implication on Agency: The agency would gain earlier insight into the feasibility and safety of devices in the US population Utilized these data to help better design the pivotal trials 12

What’s Available Now from FDA

What’s Available Now from FDA Early feasibility study (NEW!) limited clinical investigation of a device early in development may be used to evaluate the device design concept with respect to basic safety and device functionality in a small number of subjects (generally fewer than 10 initial subjects) when this information cannot be readily provided through additional nonclinical assessments or appropriate nonclinical tests are unavailable. Information obtained from an early feasibility study may guide device modifications. An early feasibility study does not necessarily involve the first clinical use of a device. First in human (FIH) study study in which a device for a specific indication is evaluated for the first time in human subjects. This document only discusses FIH studies that meet the definition of an early feasibility study. Traditional feasibility study clinical investigation that captures preliminary safety and effectiveness information on a near-final or final device design to adequately plan an appropriate pivotal study. Pivotal study clinical investigation designed to collect definitive evidence of the safety and effectiveness of a device for a specified intended use. It may or may not be preceded by an early and/or a traditional feasibility study. 14